PMID- 25629460
OWN - NLM
STAT- MEDLINE
DCOM- 20160112
LR  - 20150416
IS  - 1439-1902 (Electronic)
IS  - 0171-6425 (Linking)
VI  - 63
IP  - 3
DP  - 2015 Apr
TI  - Long-term outcomes of surgery for thymic carcinoma: experience of 25 cases at a 
      single institution.
PG  - 212-6
LID - 10.1055/s-0034-1396927 [doi]
AB  - BACKGROUND: Thymic carcinoma, a relatively rare entity, often presents as locally 
      advanced disease, and sometimes as distant metastatic disease. The treatment 
      strategy, long-term surgical outcomes and clinical prognostic factors have yet to 
      be fully elucidated. METHODS: Clinical charts of 25 patients who underwent 
      surgery for thymic carcinoma at our institution from 1991 to 2014 were 
      retrospectively reviewed. RESULTS: The Masaoka stage was stage I in three 
      patients (12%), II in eight (32%), III in four (16%), IVa in four (16%), and IVb 
      in six (24%). Histologic subtypes were squamous cell carcinoma in 12 patients, 
      well-differentiated neuroendocrine carcinoma in 5, undifferentiated carcinoma in 
      3, adenocarcinoma in 1, and others in 4. Three patients had paraneoplastic 
      syndrome including myasthenia gravis, multiple endocrine neoplasia type 1 (MEN1), 
      and Cushing syndrome. Neoadjuvant chemotherapy was administered to five patients 
      (20%). Complete resection was achieved in 17 patients (68%). There were no 
      perioperative deaths. Twelve patients received postoperative therapy. The 5- and 
      10-year overall survival rates were 76.2 and 63.5%, respectively. The 5- and 
      10-year survival rates of patients with Masaoka stage I-III were 88.9 and 74.1%, 
      respectively, whereas the 5-year survival rate of stage IV was 50.0%. The 5- and 
      10-year survival rates of 17 patients who underwent complete resection were 88.9 
      and 71.1%, respectively. Of the 17 patients with complete resection, 3 patients 
      experienced recurrence including lung and supraclavicular lymph node. CONCLUSION: 
      Even for this highly malignant disease, surgery could contribute to favorable 
      long-term outcomes in the setting of multimodality therapy.
CI  - Georg Thieme Verlag KG Stuttgart . New York.
FAU - Tagawa, Tetsuzo
AU  - Tagawa T
AD  - Department of General Thoracic Surgery, Chiba University, Chiba, Japan.
FAU - Suzuki, Hidemi
AU  - Suzuki H
AD  - Department of General Thoracic Surgery, Chiba University, Chiba, Japan.
FAU - Nakajima, Takahiro
AU  - Nakajima T
AD  - Department of General Thoracic Surgery, Chiba University, Chiba, Japan.
FAU - Iwata, Takekazu
AU  - Iwata T
AD  - Department of General Thoracic Surgery, Chiba University, Chiba, Japan.
FAU - Mizobuchi, Teruaki
AU  - Mizobuchi T
AD  - Department of General Thoracic Surgery, Chiba University, Chiba, Japan.
FAU - Yoshida, Shigetoshi
AU  - Yoshida S
AD  - Department of General Thoracic Surgery, Chiba University, Chiba, Japan.
FAU - Yoshino, Ichiro
AU  - Yoshino I
AD  - Department of General Thoracic Surgery, Chiba University, Chiba, Japan.
LA  - eng
PT  - Journal Article
DEP - 20150128
PL  - Germany
TA  - Thorac Cardiovasc Surg
JT  - The Thoracic and cardiovascular surgeon
JID - 7903387
SB  - IM
MH  - Adult
MH  - Aged
MH  - Carcinoma, Neuroendocrine/surgery
MH  - Carcinoma, Squamous Cell/drug therapy/mortality/radiotherapy/*surgery
MH  - Combined Modality Therapy
MH  - Disease-Free Survival
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Prognosis
MH  - Retrospective Studies
MH  - Survival Analysis
MH  - Thymus Neoplasms/drug therapy/mortality/radiotherapy/*surgery
MH  - Treatment Outcome
EDAT- 2015/01/30 06:00
MHDA- 2016/01/13 06:00
CRDT- 2015/01/29 06:00
PHST- 2015/01/29 06:00 [entrez]
PHST- 2015/01/30 06:00 [pubmed]
PHST- 2016/01/13 06:00 [medline]
AID - 10.1055/s-0034-1396927 [doi]
PST - ppublish
SO  - Thorac Cardiovasc Surg. 2015 Apr;63(3):212-6. doi: 10.1055/s-0034-1396927. Epub 
      2015 Jan 28.